Publication: A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia
dc.contributor.author | Gemici, Aliihsan | |
dc.contributor.author | Dogu, Mehmet Hilmi | |
dc.contributor.author | Tekinalp, Atakan | |
dc.contributor.author | Alacacioglu, Inci | |
dc.contributor.author | Guney, Tekin | |
dc.contributor.author | Ince, Idris | |
dc.contributor.author | Geduk, Ayfer | |
dc.contributor.author | Cağlıyan, Gulsum Akgun | |
dc.contributor.author | Maral, Senem | |
dc.contributor.author | Serin, Istemi | |
dc.contributor.author | Gunduz, Eren | |
dc.contributor.author | Karakus, Volkan | |
dc.contributor.author | Bekoz, Huseyin Saffet | |
dc.contributor.author | Eren, Rafet | |
dc.contributor.author | Gunes, Ahmet Kursad | |
dc.contributor.author | Sargin, Fatma Deniz | |
dc.contributor.author | Sevindik, Omur Gokmen | |
dc.contributor.buuauthor | Ozkalemkas, Fahir | |
dc.contributor.buuauthor | ÖZKALEMKAŞ, FAHİR | |
dc.contributor.buuauthor | Pinar, Ibrahim Ethem | |
dc.contributor.buuauthor | PINAR, İBRAHİM ETHEM | |
dc.contributor.department | Bursa Uludağ Üniversitesi/Tıp Fakültesi/Hematoloji Anabilim Dalı. | |
dc.contributor.researcherid | JWP-2738-2024 | |
dc.contributor.researcherid | AAA-5330-2022 | |
dc.date.accessioned | 2024-06-12T10:31:37Z | |
dc.date.available | 2024-06-12T10:31:37Z | |
dc.date.issued | 2021-08-10 | |
dc.description.abstract | Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS). A total of 60 patients with a median age of 67 years from different centers were included in the final analysis. Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML.Introduction: Venetoclax is a selective B-cell lymphoma 2 (BCL2) inhibitor, which is approved to treat elderly patients with newly diagnosed acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) in combination with either low-dose cytarabine (ARA-C) or hypomethylating agents. We aimed to collect and share data among the efficacy and safety of venetoclax both as a monotherapy or in combination with other drugs used to treat high-risk MDS or AML. Materials and Methods: A total of 60 patients with a median age of 67 (30-83) years from 14 different centers were included in the final analysis. Thirty (50%) of the patients were women; 6 (10%) of the 60 patients were diagnosed with high-risk MDS and the remaining were diagnosed with AML. Results: The best objective response rate (complete remission [CR], complete remission with incomplete hematological recovery (CRi), morphological leukemia-free state [MLFS], partial response [PR]) was 35% in the entire cohort. Best responses achieved during venetoclax per patient number were as follows: 7 CR, 1 CRi, 8 MLFS, 5 PR, and stable disease. Median overall survival achieved with venetoclax was 5 months in patients who relapsed and not achieved in patients who were initially treated with venetoclax. Nearly all patients (86.7%) had experienced a grade 2 or more hematologic toxicity. Some 36.7% of these patients had received granulocyte colony stimulating factor (GCSF) support. Infection, mainly pneumonia (26.7%), was the leading nonhematologic toxicity, and fatigue, diarrhea, and skin reactions were the others reported. Conclusion: Our real-life data support the use of venetoclax in patients with both newly diagnosed and relapsed high-risk MDS and AML. (C) 2021 Elsevier Inc. All rights reserved. | |
dc.identifier.doi | 10.1016/j.clml.2021.04.004 | |
dc.identifier.endpage | E692 | |
dc.identifier.issn | 2152-2650 | |
dc.identifier.issue | 8 | |
dc.identifier.startpage | E686 | |
dc.identifier.uri | https://doi.org/10.1016/j.clml.2021.04.004 | |
dc.identifier.uri | https://hdl.handle.net/11452/42062 | |
dc.identifier.volume | 21 | |
dc.identifier.wos | 000684596500017 | |
dc.indexed.wos | WOS.SCI | |
dc.language.iso | en | |
dc.publisher | Cig Media Group | |
dc.relation.journal | Clinical Lymphoma Myeloma & Leukemia | |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Low-dose cytarabine | |
dc.subject | Older patients | |
dc.subject | Bcl-2 inhibition | |
dc.subject | Azacitidine | |
dc.subject | Survival | |
dc.subject | Care | |
dc.subject | Aml | |
dc.subject | Bcl2 | |
dc.subject | Inhibitor | |
dc.subject | Venetoclax | |
dc.subject | Acute myeloid leukemia | |
dc.subject | Real life | |
dc.subject | Science & technology | |
dc.subject | Life sciences & biomedicine | |
dc.subject | Oncology | |
dc.subject | Hematology | |
dc.subject | Oncology | |
dc.subject | Hematology | |
dc.title | A real-life Turkish experience of venetoclax treatment in high-risk myelodysplastic syndrome and acute myeloid leukemia | |
dc.type | Article | |
dspace.entity.type | Publication | |
relation.isAuthorOfPublication | 6d4676a2-f825-4560-bfa8-c7eb6daf748d | |
relation.isAuthorOfPublication | 780690ec-9c57-47ed-a462-d5d676cd36e3 | |
relation.isAuthorOfPublication.latestForDiscovery | 6d4676a2-f825-4560-bfa8-c7eb6daf748d |
Files
Original bundle
1 - 1 of 1